Dahms Bradford D. Insider Trades

Insider Trading History

Track insider trading activity for Dahms Bradford D.. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Jade Biosciences
Jade Biosciences JBIO
Chief Financial Officer
Holding Value $4.02M 226,875 shares
Last Trade
Feb 12, 2026 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$3.92M 264,688 shares
$14.81
$17.74
Jade Biosciences
Jade Biosciences JBIO
Chief Financial Officer
Holding Value $9.33M 526,000 shares
Last Trade
Jul 14, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
No data
No data
$17.74
Theseus Pharmaceuticals
Theseus Pharmaceuticals THRX
President And CFO
Holding Value $0 0 shares
Last Trade
Feb 14, 2024 Sale (Tender)Reported as Tender on SEC Form 4.
$33k 8,150 shares
$4.05
$4.06
Theseus Pharmaceuticals
Theseus Pharmaceuticals THRX
President And CFO
Holding Value $0 0 shares
Last Trade
Feb 14, 2024 Sale (Sale to Issuer)Shares sold back to the company, such as a repurchase or tender.
$1.34M 332,114 shares
$4.03
$4.06
Theseus Pharmaceuticals
Theseus Pharmaceuticals THRX
Chief Financial Officer
Holding Value $71.1k 17,500 shares
Last Trade
Mar 01, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$155k 17,500 shares
$8.84
$4.06
Theseus Pharmaceuticals
Theseus Pharmaceuticals THRX
Chief Financial Officer
Holding Value $427k 105,000 shares
Last Trade
Feb 17, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.2M 105,000 shares
$11.42
$4.06
Theseus Pharmaceuticals
Theseus Pharmaceuticals THRX
Chief Financial Officer
Holding Value $25k 6,142 shares
Last Trade
Nov 30, 2022 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$10k 1,502 shares
$6.66
$4.06
Theseus Pharmaceuticals
Theseus Pharmaceuticals THRX
Chief Financial Officer
Holding Value $610k 150,000 shares
Last Trade
Feb 18, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.68M 150,000 shares
$11.21
$4.06
Theseus Pharmaceuticals
Theseus Pharmaceuticals THRX
Chief Financial Officer
Holding Value $8.01k 1,970 shares
Last Trade
Dec 21, 2021 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$20k 1,970 shares
$10.15
$4.06
Theseus Pharmaceuticals
Theseus Pharmaceuticals THRX
Chief Financial Officer
Holding Value $0 0 shares
Last Trade
Oct 06, 2021 Sale
No data
No data
$4.06
Selecta Biosciences
Selecta Biosciences SELB
Chief Financial Officer
Holding Value $203k 230,000 shares
Last Trade
Jan 04, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$801k 268,000 shares
$2.99
$0.88
Selecta Biosciences
Selecta Biosciences SELB
Chief Financial Officer
Holding Value $35.2k 40,000 shares
Last Trade
Jul 01, 2020 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$114k 40,000 shares
$2.84
$0.88
Selecta Biosciences
Selecta Biosciences SELB
Chief Financial Officer
Holding Value $123k 140,000 shares
Last Trade
Jan 02, 2020 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$322k 140,000 shares
$2.30
$0.88
Selecta Biosciences
Selecta Biosciences SELB
Chief Financial Officer
Holding Value $352k 400,000 shares
Last Trade
Sep 03, 2019 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$680k 400,000 shares
$1.70
$0.88

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up